RegentAtlantic Capital
NNVC icon

RegentAtlantic Capital’s NanoViricides NNVC Stock Holding History

RegentAtlantic Capital’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-143
Closed -$7.77K – 720
2014
Q4 		$7.77K Buy
+143
New +$9.47K ﹤0.01% 945

Other funds holding NNVC

BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Colony Group
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
TIAA CREF Investment Management
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

RegentAtlantic Capital's NNVC Position: Q1 2015 in Review

RegentAtlantic Capital sold out of NanoViricides (NNVC) in Q1 2015, closing a stake of 143 shares — an estimated $7.77K sold.

RegentAtlantic Capital first reported a position in NNVC in Q4 2014 and held it in 1 quarter. The position peaked at $7.77K in Q4 2014. 58 funds tracked by Wall St. Rank hold NNVC as of Q1 2015.

  • RegentAtlantic Capital reported no remaining NanoViricides position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 143 NanoViricides shares in Q1 2015, an estimated $7.77K.
  • RegentAtlantic Capital first reported a position in NanoViricides in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's NanoViricides position peaked at $7.77K in Q4 2014.
  • 58 funds tracked by Wall St. Rank held NanoViricides as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.